|Bid||65.23 x 1300|
|Ask||65.35 x 800|
|Day's Range||64.02 - 65.43|
|52 Week Range||43.51 - 72.41|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||66.34|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.50|
SAN DIEGO, Aug. 20, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the commercial launch of Modulus® TLIF-A, a porous titanium spine implant engineered for the transforaminal lumbar interbody fusion (TLIF) procedure. This offering completes the Company's Advanced Materials Science™ (AMS) portfolio for all major posterior interbody fusion techniques used in TLIF, the most commonly performed procedure in the spine industry. The availability of Modulus TLIF-A further extends NuVasive's technology offerings in the spinal deformity market given its differentiated ability to provide anterior column support, increase segmental lordosis and maximize capability to restore sagittal alignment.
SAN DIEGO, Aug. 14, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced a milestone of 10,000 implants of the Precice® system for conditions related to limb lengthening and reconstruction from NuVasive Specialized Orthopedics™. "Precice has completely changed the game in limb lengthening and reconstruction surgery and is rapidly becoming the gold standard of care for patients with conditions related to limb-length discrepancy," said Stuart Green, MD, orthopedic surgeon at UC Irvine School of Medicine. "Before Precice, patients were limited to bulky, painful external fixation devices that significantly impacted their mobility and comfort.
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
With the Beckley Canopy Therapeutics acquisition, Canopy Growth's (CGC) research and development endeavors would be expanding worldwide, thereby making the company a global pioneer in cannabinoid research.
SAN DIEGO, Aug. 8, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today is hosting its 2019 Investor Day in New York City with presentations by Chief Executive Officer J. Christopher Barry and other members of the management team. "At NuVasive's 2019 Investor Day, I look forward to sharing the Company's go-forward strategy to build on our foundation as the innovation leader in spine with a roadmap to deliver sustained, above-market growth," said J. Christopher Barry, chief executive officer of NuVasive.
NuVasive (NUVA) delivered earnings and revenue surprises of 12.50% and 0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?